270 employees
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
$8.2M sweet spot round size
Most of their 1 investments are in rounds between $8.2M and $8.2M
2013
INmune Bio Inc. raised $8.2M on February 7, 2019
Investors: Alector